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Minimum detection rates at screening are sometimes laid down as standards for breast cancer screening programmes, based on
underlying incidence of the disease in the age group screened. Detection rates should also depend on desired sensitivity, mean
sojourn time, interscreening interval and the screening round – that is, prevalent (first) or incident (second or subsequent). In this
paper, we use these quantities to derive expected, minimum and maximum detection rates proportional to the underlying incidence
as well as estimated underlying incidence rates from extrapolation of prescreening trends in England and Wales to derive alternative
standard minimum, expected and maximum detection rates per 1000 women screened for the UK Breast Screening Programme, as
follows: minimum detection rates should be 4.1 and 4.3 at prevalence screen and incidence screens, respectively; expected rates
should be 6.9 and 4.8 and maximum rates of 9.6 and 5.5. These are consistent with observed detection rates in the UK programme.
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A frequently used quality standard for mammographic screening is
the detection rate, either at prevalence (first) screen or incidence
(second or subsequent) screen. Some organisations stipulate an
absolute minimum detection rate, others a minimum rate
proportional to the underlying incidence (i.e., the incidence one
would expect if screening were not taking place).
In the UK, the NHS breast screening programme stipulates a
minimum detection rate of invasive tumours of 3.6 per 1000 at
prevalence (first) screen and 4 per 1000 at incidence (second or
subsequent) screen (NHS Breast Screening Review, 2003). These
were estimated using prevalence to incidence ratios from the
Swedish Two-county Trial, with the expected interval cancers
subtracted to give the incidence screen figure (Moss and Blanks,
1998). The reason the expected rate is higher at the incidence
screen is that in the UK programme, which invites women aged
50–64 years (currently being extended to 69 years), average age at
prevalence screen is 51 years, whereas average age at incidence
screen is 57.5 years, with a correspondingly higher incidence and
higher prevalence:incidence ratio. The European Union standard
has set a minimum detection rate of 1.5 times the underlying
incidence at second and subsequent screens (The European
Commission, 2001).
It has been pointed out that the detection rate will depend on the
underlying incidence and the interscreening interval (Sarkeala et al,
in press). The detection rate depends also on the mean sojourn
time (MST), the average duration of the preclinical screen-
detectable period, and the screening sensitivity. Finally, there is a
substantial quantitative difference between prevalence and in-
cidence screening, even if the underlying incidences were equal.
This is because a prevalence screen detects (subject to sensitivity)
the cancers in the large prevalence pool. For incidence screening,
many of these prevalence pool cancers have already been detected
at the previous screen, so the detection rate at the incidence screen
may be smaller than at the prevalence screen. These considerations
are implicit in the calculations of Moss and Blanks (1998), but it is
worthwhile to formalise them further, and to avoid explicitly
calculating the expected interval cancers.
In this paper, we calculate the expected proportional detection
rates for the prevalence and incidence screens for given sensitivity,
interval length and MST (or its reciprocal, the rate of progression
from preclinical screen-detectable to symptomatic clinical disease).
We estimate the underlying incidence rates in England and Wales,
and use these in turn to estimate the expected detection rates in the
UK programme. Finally, we suggest new minimum and maximum
standards for detection rates in the UK programme.
METHODS
Let M represent the mean sojourn time and S the screening
test sensitivity. Assume a screening interval of r years. Let I
represent the underlying incidence and let l¼1/M be the rate of
transition from preclinical to clinical disease. Paci and Duffy
(1991) show that the expected detection rate at prevalence screen is
P ¼ IMS
The above rate is for an age group within which incidence and
MST are roughly homogeneous. Strictly speaking, P, I, M and S are
potentially functions of age. This can be seen intuitively since the
size of the prevalence pool will be the incidence (I) times the
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yaverage time spent in the prevalence pool (M), and the sensitivity
will be the proportion of these tumours detectable at first screen.
The proportional detection rate will be
Ps ¼ MS
At incidence screens, the expected detection rate is more
complicated. Launoy et al (Launoy et al, 1998; Launoy and Prevost,
2001) show that in steady-state incidence screening, the pro-
gramme sensitivity, that is, the proportion of tumours diagnosed
within the programme that are screen-detected is
Sp ¼
Sð1   e lrÞ
lrð1  ð 1   SÞe lrÞ
If the expected detection rate of tumours at an incidence screen
is Q, we have
Q ¼ IrSp
Therefore,
Q ¼
Sð1   e lrÞI
lð1  ð 1   SÞe lrÞ
To obtain the proportional detection rate at incidence screens,
we divide by I
Qs ¼
Sð1   e lrÞ
lð1  ð 1   SÞe lrÞ
To obtain underlying incidences, we estimated the expected
underlying rates for the year 2000 by extrapolation of trends in
incidence observed in 1982–1988, before the UK screening
programme started. The trends were estimated by Poisson
regression (Breslow and Day, 1987), in which the logarithms of
the age-specific incidence rates were assumed to increase linearly
over calendar time. The reason for the latter approach is to
estimate the incidence which would have been obtained had
screening not taken place. The screening programme itself is
likely to have affected the incidence of breast cancer, notably in
the ages of 50–54 years in which most of the prevalence screening
takes place.
RESULTS
Proportional detection rates
Tabar et al (2000) found MSTs of 2.4, 3.7, 4.2 and 4.0 years for the
age groups 40–49, 50–59, 60–69 and 70–74 years, respectively. In
the age group of 50–64 years, typical estimates of the MST are
around 3–4 years (Paci and Duffy, 1991; Tabar et al, 2000; Shen
and Zelen, 2001) and sensitivity is generally high, in excess of 90%.
A 2:1 weighted average of the Tabar results for 50–59 and 60–69
years is 3.9 years, which is an estimate appropriate to the age
group of 50–64 years. Incidence screens in the UK will on average
be in the middle of this range. Prevalence screens, however, will
be in the lower 50s, suggesting that a 2:1 weighted average of the
estimate for 50–59 and 40–49 years age groups is more
appropriate for prevalence screens. This is calculated as 3.3 years.
With 90% sensitivity, the proportional detection rate at a
prevalence screen would therefore be expected to be around
Ps ¼ 3:3 0:9 ¼ 3:0
That is, one would expect around three times the underlying
incidence at a prevalence screen. At incidence screening, with a
3-year interval, one would expect a proportional detection rate of
Qs ¼
0:9ð1   e 0:26 3Þ
0:26ð1  ð 1   0:9Þe 0:26 3Þ
¼ 1:98
since 0.26¼1/3.9. Thus, one would expect approximately double
the underlying annual incidence rate at incidence screens. We
would not expect these to be mammography standards, since there
will be some natural variation around them. A minimum
sensitivity of 85% might be reasonable and confidence intervals
on estimates of MST suggest that it is unlikely to be lower than 2.1
years for the age at prevalence screen and 3.4 years for the age at
incidence screens (Tabar et al, 2000). It has also been suggested
that upper limits be specified (Sarkeala et al, in press) as a possible
indicator of overdiagnosis. An MST higher than 4.2 years for age at
prevalence screens and 4.6 years for age at incidence screens is
unlikely (Tabar et al, 2000), and clearly the test sensitivity cannot
be higher than 100%. Table 1 therefore gives the expected
proportional detection rates (M¼3.3 or 3.9, S¼90%), the lower
limits (M¼2.1 or 3.4, S¼85%) and the upper limits (M¼4.2 or
4.6, S¼100%), for prevalence and incidence screens with 1, 2 and
3-year interscreening intervals.
Absolute detection rates in the UK programme
To obtain detection rates for the UK National Breast Screening
Programme, we need estimates of the underlying incidence. Table 2
shows the estimated incidence rates by extrapolation of the
prescreening trends in 1982–1988, in 5-year age groups. The
average age at incidence screens of 57.5 years suggests that the
most suitable estimate of underlying incidence should be that for
the ages 55–59 years. If the average age at prevalence screen is 51
years, the appropriate estimated underlying incidence should be a
weighted average of the 45–49 and 50–54 year rates, weighting the
first by 0.3 and the latter by 0.7.
Table 3 shows the underlying incidences per 100000 based
on the estimated rates, and the corresponding expected,
minimum and maximum absolute detection rates per 1000, for
prevalence and incidence screens. The incidence screen rates are
based on the 3-year interval in the UK programme. This
suggests the standard that the prevalence screen detection rates
lie between 4.1 and 9.6 per 1000 and the incidence screen rates
between 4.3 and 5.5 per 1000.
Table 1 Expected minimum and maximum proportional detection rates
for prevalence and incidence screens, by interscreening interval, assuming a
screening age range of 50–64 years
Detection rates
Screen (interval) Minimum Expected Maximum
Prevalence 1.8 3.0 4.2
Incidence (1 year) 0.8 0.9 1.0
Incidence (2 year) 1.4 1.5 1.7
Incidence (3 year) 1.8 2.0 2.3
Table 2 Age-specific incidence rates per 100000 person-years of breast
cancer in the year 2000, estimated by extrapolation of prescreening trends
Age group (years) Incidence estimated
45–49 213.7
50–54 236.6
55–59 241.0
60–64 430.5
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The stipulation of standards for detection rates should take
account the underlying incidence, the screening interval, the MST
and the desired test sensitivity. We have derived estimates of
proportional detection rates for prevalence and incidence screens
based on these, with suggested minima and maxima. In addition,
we have applied estimated UK incidence rates to derive standards
for the UK National Breast Screening Programme.
One point of caution is that our projected underlying incidence
rates differ from the actual observed incidence rates in recent
years. The observed incidences in the year 2000 for the four age
groups in Table 2 were, respectively, 182.7, 275.2, 284.8 and 311.7
per 100000. The fact that the estimated rates for ages 50–59 years
are lower than observed is desirable, since we require the
underlying incidence without the artificial observed increase due
to screening. The estimated rates higher than observed for ages
45–49 and 60–64 years, however, suggest that trends in incidence
have been more complex than modelled here. The recommended
detection rates using the observed rather than estimated incidence
rates would be 6.7 at prevalence screen (minimum 5.2–maximum
11.1) and 5.1 at incidence screens (minimum 4.3, maximum 6.3).
We recommend that the prevalence screen detection rates lie in
the range 4.1–9.6 per 1000 and incidence screen rates in the range
4.3–5.5 per 1000. The observed rates of 5.4 per 1000 at prevalence
and 4.7 per 1000 at incidence screens satisfy both criteria (NHS
Breast Screening Review, 2003). We also suggest that three figures
might be stipulated in monitoring of screening programmes: a
minimum standard, corresponding to our minimum detection
rate, a desirable standard to aim at, corresponding to our expected
rate, and a maximum, above which further investigation would
take place. In the UK programme, the detection rate at prevalence
screen is around halfway between our minimum and expected rate,
and the rate at incidence screen is very close to our expected.
Our minimum detection rates differ only slightly from existing
ones, being around 10% higher. Our expected and maximum
detection rates are higher for the prevalence screen than for the
incidence screens despite the higher underlying incidence for the
latter. This is because the size of the likely pool of occult cases at
prevalence screen outweighed the difference in incidence. In
practice, a higher rate at prevalence screening is observed in the
UK programme (NHS Breast Screening Review, 2003).
It could be argued that our range for the prevalence screen is too
wide. This is due to the fact that we have taken conservatively the
lower point of the 95% confidence interval on the MST at the ages
40–49 years as the minimum and the upper point of the interval at
ages 50–59 years as the maximum (Tabar et al, 2000), which is
probably conservative due to relative imprecision in the lower age
group. Using a formal confidence interval on the weighted average
sojourn time of 3.3 would give upper and lower limits for the
prevalence screen detection rates of 5.6 and 9.2 per 1000. This is
still a rather wide range, due to the uncertainty in estimation of
sojourn time at younger ages in which incidence is relatively low.
To improve upon this, it would be useful to have large scale
interval cancer data from the UK screening programme in order to
estimate more precisely the MST in women in their early 50s. Thus,
while we believe our methodology is useful and the estimates are
reliable, we anticipate that the prevalence screen range could be
substantially narrowed with the availability of the appropriate data
for precise estimation.
For programmes in other countries, our proportional
incidences in Table 1 can be combined with the relevant
interscreening intervals and underlying incidences to derive
approximate standards. If, however, the age range is different,
the likely sensitivity and MST will change. For example, in
screening women aged 40–49 years, both MST and sensitivity will
be lower.
The UK National Breast Screening Programme is in the process
of extending the upper limit to 69 years. When this has been
completed, the average age at incidence will be around 60 years. In
this case, the appropriate underlying incidence should be the
average of the 55–59 and 60–64 year incidences, but the MST
would change only very slightly, if at all (Tabar et al, 2000). The
estimated incidence would be 335.8 per 100000. This would give a
range for the detection rate at incidence screen of 6.0–8.2 per 1000
and an expected rate of 6.7 per 1000.
Our methods depend on several assumptions. We assume a
homogeneous exponential distribution of time to progression from
preclinical to clinical disease for given age. The exponential
distribution assumption is reasonable, although it is possible that
there is a mixture of populations, one with a long sojourn time and
one with a short. This would lead to a greater overall sojourn time
of prevalence screen tumours than incidence screen. The homo-
geneous model and the exponential distribution have, however,
given a reasonable fit to breast screening data in the past (Day and
Walter, 1984).
In conclusion, taking account of sojourn time, sensitivity and
screening interval, in addition to incidence has yielded new
estimates of the likely detection rates in breast screening. The
standard minima and maxima suggested by these new rates are
consistent with observed rates in the UK programme.
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